Proof of concept of a multimodal intravital molecular imaging system for tumour transpathology investigation.

Liu, Zhen; Cheng, Tao; Düwel, Stephan; Jian, Ziying; Topping, Geoffrey J; Steiger, Katja; Wang, Qian; Braren, Rickmer; Reder, Sybille; Mittelhäuser, Markus; Hundshammer, Christian; Feuerecker, Benedikt; Huang, Sung-Cheng; Schwaiger, Markus; Schilling, Franz; Ziegler, Sibylle I; Shi, Kuangyu (2022). Proof of concept of a multimodal intravital molecular imaging system for tumour transpathology investigation. European journal of nuclear medicine and molecular imaging, 49(4), pp. 1157-1165. Springer 10.1007/s00259-021-05574-y

[img]
Preview
Text
2021_Article_.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

BACKGROUND

Transpathology highlights the interpretation of the underlying physiology behind molecular imaging. However, it remains challenging due to the discrepancies between in vivo and in vitro measurements and difficulties of precise co-registration between trans-scaled images. This study aims to develop a multimodal intravital molecular imaging (MIMI) system as a tool for in vivo tumour transpathology investigation.

METHODS

The proposed MIMI system integrates high-resolution positron imaging, magnetic resonance imaging (MRI) and microscopic imaging on a dorsal skin window chamber on an athymic nude rat. The window chamber frame was designed to be compatible with multimodal imaging and its fiducial markers were customized for precise physical alignment among modalities. The co-registration accuracy was evaluated based on phantoms with thin catheters. For proof of concept, tumour models of the human colorectal adenocarcinoma cell line HT-29 were imaged. The tissue within the window chamber was sectioned, fixed and haematoxylin-eosin (HE) stained for comparison with multimodal in vivo imaging.

RESULTS

The final MIMI system had a maximum field of view (FOV) of 18 mm × 18 mm. Using the fiducial markers and the tubing phantom, the co-registration errors are 0.18 ± 0.27 mm between MRI and positron imaging, 0.19 ± 0.22 mm between positron imaging and microscopic imaging and 0.15 ± 0.27 mm between MRI and microscopic imaging. A pilot test demonstrated that the MIMI system provides an integrative visualization of the tumour anatomy, vasculatures and metabolism of the in vivo tumour microenvironment, which was consistent with ex vivo pathology.

CONCLUSIONS

The established multimodal intravital imaging system provided a co-registered in vivo platform for trans-scale and transparent investigation of the underlying pathology behind imaging, which has the potential to enhance the translation of molecular imaging.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Shi, Kuangyu

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1619-7089

Publisher:

Springer

Language:

English

Submitter:

Daria Vogelsang

Date Deposited:

10 Jan 2022 10:20

Last Modified:

16 Mar 2022 00:12

Publisher DOI:

10.1007/s00259-021-05574-y

PubMed ID:

34651225

Uncontrolled Keywords:

Fiducial marker Glycolysis imaging Intravital imaging Multimodal imaging Positron imaging Transpathology Tumour microenvironment Window chamber

BORIS DOI:

10.48350/162494

URI:

https://boris.unibe.ch/id/eprint/162494

Actions (login required)

Edit item Edit item
Provide Feedback